- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00825916
A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars
September 10, 2012 updated by: Capstone Therapeutics
A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Paddington Testing Company, Inc.
-
-
Texas
-
Austin, Texas, United States, 78759
- Dermresearch, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- keloid scar between 1 and 3 cm long, less than 1 cm at its widest point
- willing to undergo keloid scar removal surgery
- healthy adult male or non-pregnant female
- non-diabetic
- Body Mass Index in the range of 18-35
- no clinically significant abnormal values on a full blood safety screen
- non-smoker and non-nicotine user for the previous six months
Exclusion Criteria:
- history or clinical evidence of acute or chronic disease
- history of malignant neoplasm within the last 5 years, except for surgically removed cancers of the skin that are not on the keloid area
- history of anaphylactic shock or anaphylactoid (hypersensitivity) reaction
- allergy to local anesthesia, including lidocaine and epinephrine
- ongoing dermatologic disorders, except for folliculitis and acne
- on therapy with steroids
- on therapy with a drug that would affect collagen synthesis
- positive urine test for nicotine or drugs of abuse
- positive blood test for HIV 1 or 2, hepatitis B or hepatitis C
- positive blood test for anti-AZX100 antibodies
- participation in another study within 60 days prior to enrollment
- donate blood within 7 days before dosing with study drug
- donate plasma within 3 days before dosing with study drug
- have a tattoo within 3 cm of the keloid scar that will be removed
- apply any lotion or cream on or near the keloid scar that will be removed within 14 days before dosing with study drug
- use a tanning bed or tanning light within 3 months before enrollment
- intend to use any scar improving product during the study (one year)
- history of drug addiction or excessive use of alcohol
- previous drug treatment of the keloid scar that will be removed within the last 3 years; any laser, irradiation, or surgery of the keloid scar that will be removed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal.
The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
|
Experimental: High Dose
|
Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal.
The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal.
The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
|
Experimental: Low Dose
|
Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal.
The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal.
The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores
Time Frame: 12 Months
|
Efficacy was based on the difference between mean POSAS scores of placebo, 3 mg AZX100, and 10 mg AZX100 12 months after surgery.
This gave four comparisons to placebo: patient or observer and 3 mg and 10 mg AZX100.
PSAS included patients' ratings on a scale of 1-10 (1 was normal skin or no complaints and 10 was the worst imaginable scar or the worst difference) for the following: Is the scar painful?
Is the scar itching?
Is the color of the scar different?
Is the scar more stiff?
Is the thickness of the scar different?
Is the scar irregular?
The possible minimum score was 6 and the maximum (worst) score was 60.
OSAS included observers' ratings on a scale of 1-10 (1 was normal skin and 10 was the worst scar imaginable) for vascularization, pigmentation, thickness, relief, and pliability.
The possible minimum score was 5 and the possible maximum (worst) score was 50.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Between-group Mean Differences in Visual Analog Scale (VAS) Scores by Independent Blinded Raters
Time Frame: 12 months
|
At 12 months, two independent dermatologists who were blinded to study treatment evaluated the scar images using a Visual Analog Scale (VAS) of 0-100 millimeters (mm), with 0 being normal skin and 100 being the worst scar imaginable.
The scars were presented in longitudinal (chronological) order.
Efficacy was based on the difference between VAS scores of placebo and 3 mg AZX100, and placebo and 10 mg AZX100 for each of the two raters separately.
Data from the two raters was not combined.
|
12 months
|
Between-group Mean Differences in Objective Measures Obtained Via 3D Photography (Elevation, Length, Width)
Time Frame: 12 months
|
This secondary outcome included scar measurements based on 3D photography of the scar surface at Month 12 and included maximum length, maximum width perpendicular to maximum length, and minimum, maximum and mean elevation.
All elevation measurements were made relative to the interpolated smooth skin surface.
A value closest to zero was preferred because zero was equal to the normal skin surface.
The minimum elevation value was calculated as the lowest point of the scar below the interpolated smooth skin surface and was always a negative number.
A more negative number was worse because it indicated a deeper measurement below the interpolated smooth skin surface.
The maximum elevation value was calculated as the highest point of the scar above the interpolated smooth skin surface.
A larger number was worse because it indicated a higher peak above the interpolated smooth skin surface.
The mean elevation of the scar relative to the interpolated smooth skin surface was also calculated.
|
12 months
|
Between-group Mean Differences in Objective Measures Obtained Via 3D Photography (Volume)
Time Frame: 12 months
|
This secondary outcome included measurements based on 3D photography of the scar surface at Month 12 and included positive volume, negative volume, and total volume.
All volume measurements were made relative to the interpolated smooth skin surface.
A value closer to zero was preferred, because zero was equal to the normal skin surface.
Positive volume was calculated as the volume of the scar above the interpolated smooth skin surface.
Negative volume was calculated as the volume of the scar below the smooth interpolated skin surface, and was always a negative number.
Total volume was calculated as the sum of positive volume and the absolute value of negative volume.
Smaller values were more desirable.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
July 1, 2010
Study Registration Dates
First Submitted
January 20, 2009
First Submitted That Met QC Criteria
January 20, 2009
First Posted (Estimate)
January 21, 2009
Study Record Updates
Last Update Posted (Estimate)
October 11, 2012
Last Update Submitted That Met QC Criteria
September 10, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OL-ASCAR-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scar Prevention
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Lumenis Be Ltd.Terminated
-
PfizerCompletedScar PreventionUnited States
-
Thammasat University HospitalActive, not recruiting
-
PfizerCompleted
-
PfizerCompletedScar PreventionUnited States
-
Lemonex Inc.CompletedCicatrix | Scar PreventionKorea, Republic of
-
RXi Pharmaceuticals, Corp.CompletedCicatrix | Scar PreventionUnited States
-
RXi Pharmaceuticals, Corp.Completed
-
Hallym University Kangnam Sacred Heart HospitalRecruitingIntense Pulsed Light | Erbium-yttrium Aluminum Garnet Laser | Scar PreventionKorea, Republic of
Clinical Trials on AZX100 Drug Product
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingArtemis (DCLRE1C ) Deficient Severe Combined ImmunodeficiencyFrance
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
Lumosa Therapeutics Co., Ltd.UnknownAcute Ischemic StrokeTaiwan, United States
-
Lumosa Therapeutics Co., Ltd.Not yet recruiting
-
Lumosa Therapeutics Co., Ltd.Not yet recruiting
-
Regenera Pharma LtdTransCom Global Ltd. (CRO)Terminated
-
First Affiliated Hospital of Guangxi Medical UniversityGenmedicn Biopharma Ltd.RecruitingTransfusion-dependent α-ThalassemiaChina